you'll hear MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes

New concerns about bladder cancer mean you'll hear MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes.

Pioglitazone is off the market in France while authorities investigate. Regulators in other countries are also assessing its risks.

Advise keeping the potential risk in perspective.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote